TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE

核医学中的锝和铼

• 批准号: 2088804
• 负责人: Alun Gareth Jones
• 金额: $ 53.07万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 1977
• 资助国家: 美国
• 起止时间: 1977-02-01 至 1996-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2088804
• 关键词: cardiography; chemical structure function; chemical synthesis; electron probe spectrometry; guinea pigs; heart disorder diagnosis; heart metabolism; imaging /visualization /scanning; isolation perfusion; laboratory mouse; laboratory rabbit; laboratory rat; myocardial ischemia /hypoxia; neoplasm /cancer radiodiagnosis; nuclear magnetic resonance spectroscopy; nuclear medicine; radionuclide diagnosis; radiopharmacology; radiotracer; technetium

The artificial element technetium, in the form of its short-lived gamma ray emitting radionuclide 99mTc, plays a very important role in routine nuclear medicine imaging. More than 85% of all procedures in the USA involve the administration of a 99mTc-labeled radiopharmaceutical. This renewal application describes a continuing program of research that combined basic chemical studies of the element together with applications of that chemistry towards the design of new imaging agents. In addition a parallel program will explore the chemistry of the closely related metallic element rhenium and its applications in radiotherapy. The basic studies of technetium will include the use of new synthetic intermediates discovered in the current cycle to explore the rapidly developing low-oxidation-state chemistry, the use of nitrogen donor ligands to form new complexes in low and high oxidation states, and an investigation of its organometallic chemistry. New strategies will be investigated for conjugation of technetium to biologically active molecules using several different classes of complexes that leave free coordinating sites for the attachment of biological ligands. The first application of the chemistry will involve an investigation of a variety of cationic technetium complexes as myocardial imaging agents that are sensitive to the metabolic state of the tissue. Such agents would be important in the evaluation of salvageable tissue following an ischemic event. The second area will explore several avenues towards tumor detection, including relatively simple cationic complexes and 99mTc-labeled natural killer (NK) cells. In the applications of rhenium chemistry, reliable methods for synthesizing required compounds at tracer concentrations will be devised. This will essentially parallel earlier developments in technetium chemistry. This chemistry will then be applied to a search for soluble agents suitable for radiation synovectomy, particularly for treatment of rheumatoid arthritis and pigmented villonodular synovitis. The use of soluble agents may allow a wider use of this therapy in joints smaller than the knee and ankle.

人造元素锶，以其短暂的伽马射线的形式 放射性核素99mTc1在常规核生产中起着非常重要的作用 医学成像。在美国，超过85%的程序涉及 99mTc标记的放射性药物的给药。此次续订 应用描述了一项持续的研究计划，该计划结合了BASIC 元素的化学研究及其应用 化学转向新型显像剂的设计。此外，还有一个类似的 该计划将探索密切相关的金属元素的化学 铼及其在放射治疗中的应用。 氚的基础研究将包括使用新的合成材料 在当前周期中发现的中间体快速探索 发展低氧化态化学，使用氮给体配体 在低氧化态和高氧化态形成新的络合物，以及一个 对其有机金属化学的研究。新的战略将是 氚与生物活性分子偶联的研究 使用几种不同类别的络合物，使其自由配位 生物配体的附着点。的第一个应用 该化学将涉及对各种阳离子的研究 作为心肌显像剂的氚络合物对 组织的代谢状态。这样的代理将在 缺血事件后可挽救组织的评估。第二 该区域将探索几种检测肿瘤的方法，包括 相对简单的阳离子络合物和99mTc标记的自然杀伤分子(NK) 细胞。在Re化学的应用中，可靠的方法 将设计在示踪剂浓度下合成所需的化合物。 这基本上将与早期的氚发展同步进行。 化学反应。然后，这种化学将被应用于寻找可溶的 适用于放射性滑膜切除术的药剂，特别是用于治疗 类风湿性关节炎和色素沉着绒毛结节性滑膜炎。对.的使用 可溶性制剂可能会使这种疗法在小于 膝盖和脚踝。